Alaunos Therapeutics
TCRTAlgoritmens signaler
- ›Pris över MA50
- ›Hög volatilitet (274% årlig)
- ›+171% från 52v-botten
- ›Ökad handelsvolym (+1617%)
- ›-57% från 52v-toppen
📰 Senaste nyheter & analys
Källor: Placera, Nyhetsbyrån Direkt, Google NewsAlaunos Therapeutics, Inc. Estimates – NASDAQ:TCRT - TradingView
2026-10-23Alaunos Therapeutics, Inc. Estimates – NASDAQ:TCRT TradingView
TradingViewTCRT Stock Explodes As Alaunos Lands $350M Velaris Deal - Timothy Sykes
2026-10-16TCRT Stock Explodes As Alaunos Lands $350M Velaris Deal Timothy Sykes
Timothy SykesTwo 9.99% holders agree to back merger votes in Alaunos (TCRT)'s conditional repurchase deal. - Stock Titan
2026-10-15Two 9.99% holders agree to back merger votes in Alaunos (TCRT)'s conditional repurchase deal. Stock Titan
Stock TitanWhy is Alaunos Therapeutics Stock Trading 200% Higher on Tuesday? - Benzinga
2026-10-13Why is Alaunos Therapeutics Stock Trading 200% Higher on Tuesday? Benzinga
BenzingaBiotech Stock Alaunos Therapeutics (NASDAQ: TCRT) Sees Triple Digit Gains on Acquisition and Funding - Investorideas.com
2026-10-13Biotech Stock Alaunos Therapeutics (NASDAQ: TCRT) Sees Triple Digit Gains on Acquisition and Funding Investorideas.com
Investorideas.comAlaunos Therapeutics Completes Velaris Acquisition; Shares Surge - Yahoo Finance
2026-10-13Alaunos Therapeutics Completes Velaris Acquisition; Shares Surge Yahoo Finance
Yahoo FinanceAlaunos Therapeutics Completes Velaris Acquisition; Shares Surge - marketscreener.com
2026-10-13Alaunos Therapeutics Completes Velaris Acquisition; Shares Surge marketscreener.com
marketscreener.comAlaunos Therapeutics Reports Encouraging Early Obesity Drug Results - Stocktwits
2026-05-26Alaunos Therapeutics Reports Encouraging Early Obesity Drug Results Stocktwits
StocktwitsValion Bio Appoints Melinda Lackey as General Counsel
2026-05-04Valion Bio Appoints Melinda Lackey as General Counsel PR Newswire SAN ANTONIO, May 4, 2026 Seasoned Biopharmaceutical Attorney with Deep IP, Clinical-Stage, and Nasdaq Public Company Experience Joi
Tivic Health SystemsPR NewswireWaterMill Asset Management Issues Statement Regarding Consent Solicitation at Ziopharm Oncology
2020-12-17WaterMill Asset Management Corp. (together with its affiliates, “WaterMill” or “we”), a sizable and long-term shareholder of Ziopharm Oncology, Inc. (NASDAQ: ZIOP) (“Ziopharm” or the “Company”), today
ZIOPHARM Oncology IncBusiness WireWaterMill Asset Management Addresses Ziopharm Oncology’s Latest Distortion and Recent Threat
2020-12-12WaterMill Asset Management Corp. (together with its affiliates, “WaterMill” or “we”) today responded to the latest element of the low-road campaign that Ziopharm Oncology, Inc. (NASDAQ: ZIOP) (“Ziopha
ZIOPHARM Oncology IncBusiness WireWaterMill Asset Management Reinforces the Need for Meaningful and Urgent Change at Ziopharm Oncology
2020-12-08WaterMill Asset Management Corp. (together with its affiliates, “WaterMill” or “we”), which collectively with the other participants in its consent solicitation beneficially owns approximately 3.3% of
ZIOPHARM Oncology IncBusiness WireGlass Lewis Recommends Ziopharm Shareholders Vote on the WHITE Consent Card for All of WaterMill’s Director Candidates and Proposals
2020-12-03WaterMill Asset Management Corp. (together with its affiliates, “WaterMill” or “we”) today announced that Glass, Lewis & Co., LLC (“Glass Lewis”), a leading proxy advisory firm, has endorsed its case
ZIOPHARM Oncology IncBusiness WireWaterMill Asset Management Refutes Ziopharm Oncology’s Desperate, Low-Road Smear Campaign
2020-11-28WaterMill Asset Management Corp. (together with its affiliates, “WaterMill” or “we”), which collectively with the other participants in its consent solicitation beneficially owns approximately 3.3% of
ZIOPHARM Oncology IncBusiness WireISS Recommends Ziopharm Shareholders Vote for Change on WaterMill Asset Management’s WHITE Consent Card
2020-11-26WaterMill Asset Management Corp. (together with its affiliates, “WaterMill” or “we”), which collectively with the other participants in its consent solicitation beneficially owns approximately 3.3% of
ZIOPHARM Oncology IncBusiness WireWaterMill Asset Management Sets the Record Straight Following Ziopharm’s Apparent Attempt to Mislead Shareholders and Rewrite History
2020-11-24WaterMill Asset Management Corp. (together with its affiliates, “WaterMill” or “we”), which collectively with the other participants in its consent solicitation beneficially owns approximately 3.3% of
ZIOPHARM Oncology IncBusiness Wire
Klicket på "Köp i Nordnet" öppnar din Nordnet-app om installerad — där loggar du in med BankID. Annars öppnas Nordnets webbsajt där du kan logga in med BankID på samma sätt.